PMV Pharma prices $50.8M public offering of common stock and warrants

PMV Pharmaceuticals, Inc.

Priced offering of 22,055,000 shares and pre-funded warrants for 19,900,000 shares, each with accompanying warrants for 41,955,000 shares total.
Combined offering price $1.21 per share/warrant; gross proceeds ~$50.8M, net ~$47.0M.
Proceeds to fund late-stage development, regulatory submission, and commercialization prep for rezatapopt.
Warrants exercisable immediately, expire in 5 years; exercise price resets to 33% of initial upon FDA acceptance of rezatapopt NDA.
Offering expected to close September 2, 2026; TD Cowen sole book-runner.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.